When CELLINK released the first universal bioink in 2016 and subsequently launched the world’s first affordable 3D bioprinter, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting. Today, the company’s bioinks, bioprinters, software and services have been cited in 1400+ publications and are trusted by 1,600+ academic, pharmaceutical and industrial labs. With a comprehensive portfolio CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors.